Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice

• Published in: The Journal of neuroscience Vol. 34; no. 28; pp. 9222 - 9234
• Main Authors: Rao, Mala V, McBrayer, Mary Kate, Campbell, Jabbar, Kumar, Asok, Hashim, Audrey, Sershen, Henry, Stavrides, Philip H, Ohno, Masuo, Hutton, Michael, Nixon, Ralph A
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 09-07-2014
• Subjects: Animals; Behavior, Animal - drug effects; Calcium-Binding Proteins - administration & dosage; Calpain - antagonists & inhibitors; Calpain - metabolism; Cysteine Proteinase Inhibitors - administration & dosage; Female; Longevity - drug effects; Male; Mice; Mice, Transgenic; Nerve Degeneration - pathology; Nerve Degeneration - physiopathology; Nerve Degeneration - prevention & control; Survival Rate; tau Proteins - drug effects; tau Proteins - genetics; Tauopathies - pathology; Tauopathies - physiopathology; Tauopathies - prevention & control; Treatment Outcome; fractionation; nesting behavior; calcium; insoluble extracts; ambulatory movements
• ISSN: 0270-6474; 1529-2401
• DOI: 10.1523/jneurosci.1132-14.2014

Tau pathogenicity in Alzheimer's disease and other tauopathies is thought to involve the generation of hyperphosphorylated, truncated, and oligomeric tau species with enhanced neurotoxicity, although the generative mechanisms and the implications for disease therapy are not well understood. Here, we report a striking rescue from mutant tau toxicity in the JNPL3 mouse model of tauopathy. We show that pathological activation of calpains gives rise to a range of potentially toxic forms of tau, directly, and by activating cdk5. Calpain overactivation in brains of these mice is accelerated as a result of the marked depletion of the endogenous calpain inhibitor, calpastatin. When levels of this inhibitor are restored in neurons of JNPL3 mice by overexpressing calpastatin, tauopathy is prevented, including calpain-mediated breakdown of cytoskeletal proteins, cdk5 activation, tau hyperphosphorylation, formation of potentially neurotoxic tau fragments by either calpain or caspase-3, and tau oligomerization. Calpastatin overexpression also prevents loss of motor axons, delays disease onset, and extends survival of JNPL3 mice by 3 months to within the range of normal lifespan. Our findings support the therapeutic promise of highly specific calpain inhibition in the treatment of tauopathies and other neurodegenerative states.